Genetic Technologies Limited (GENE) Stock Competitors & Peer Comparison
See (GENE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GENE | $0.77 | +0.00% | 111.2M | -38.25 | -$0.02 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.74% |
| TMO | $472.80 | -1.91% | 175.7B | 26.02 | $18.17 | +0.37% |
| DHR | $184.30 | -1.25% | 130.5B | 35.72 | $5.16 | +0.74% |
| IDXX | $562.16 | -0.46% | 44.3B | 41.30 | $13.61 | N/A |
| A | $135.44 | -2.12% | 38.3B | 27.26 | $4.97 | +0.56% |
| NTRA | $215.31 | -3.06% | 30.8B | -132.91 | -$1.62 | N/A |
| IQV | $183.45 | -1.84% | 30.6B | 22.79 | $8.05 | N/A |
| ILMN | $162.32 | -3.42% | 24.6B | 29.51 | $5.50 | N/A |
| WAT | $365.36 | -2.95% | 23.8B | 46.44 | $7.87 | N/A |
Stock Comparison
GENE vs DHR-PB Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GENE is priced at $0.77, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GENE's ROE is -1.85%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GENE is less volatile compared to DHR-PB. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check DHR-PB's competition here
GENE vs TMO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, TMO has a market cap of 175.7B. Regarding current trading prices, GENE is priced at $0.77, while TMO trades at $472.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas TMO's P/E ratio is 26.02. In terms of profitability, GENE's ROE is -1.85%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GENE is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check TMO's competition here
GENE vs DHR Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DHR has a market cap of 130.5B. Regarding current trading prices, GENE is priced at $0.77, while DHR trades at $184.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DHR's P/E ratio is 35.72. In terms of profitability, GENE's ROE is -1.85%, compared to DHR's ROE of +0.07%. Regarding short-term risk, GENE is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check DHR's competition here
GENE vs IDXX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, IDXX has a market cap of 44.3B. Regarding current trading prices, GENE is priced at $0.77, while IDXX trades at $562.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas IDXX's P/E ratio is 41.30. In terms of profitability, GENE's ROE is -1.85%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, GENE is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check IDXX's competition here
GENE vs A Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, A has a market cap of 38.3B. Regarding current trading prices, GENE is priced at $0.77, while A trades at $135.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas A's P/E ratio is 27.26. In terms of profitability, GENE's ROE is -1.85%, compared to A's ROE of +0.21%. Regarding short-term risk, GENE is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check A's competition here
GENE vs NTRA Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NTRA has a market cap of 30.8B. Regarding current trading prices, GENE is priced at $0.77, while NTRA trades at $215.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NTRA's P/E ratio is -132.91. In terms of profitability, GENE's ROE is -1.85%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, GENE is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NTRA's competition here
GENE vs IQV Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, IQV has a market cap of 30.6B. Regarding current trading prices, GENE is priced at $0.77, while IQV trades at $183.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas IQV's P/E ratio is 22.79. In terms of profitability, GENE's ROE is -1.85%, compared to IQV's ROE of +0.22%. Regarding short-term risk, GENE is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check IQV's competition here
GENE vs ILMN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ILMN has a market cap of 24.6B. Regarding current trading prices, GENE is priced at $0.77, while ILMN trades at $162.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ILMN's P/E ratio is 29.51. In terms of profitability, GENE's ROE is -1.85%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, GENE is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check ILMN's competition here
GENE vs WAT Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, WAT has a market cap of 23.8B. Regarding current trading prices, GENE is priced at $0.77, while WAT trades at $365.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas WAT's P/E ratio is 46.44. In terms of profitability, GENE's ROE is -1.85%, compared to WAT's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check WAT's competition here
GENE vs MTD Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MTD has a market cap of 23.3B. Regarding current trading prices, GENE is priced at $0.77, while MTD trades at $1,154.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MTD's P/E ratio is 27.08. In terms of profitability, GENE's ROE is -1.85%, compared to MTD's ROE of -6.10%. Regarding short-term risk, GENE is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MTD's competition here
GENE vs DGX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DGX has a market cap of 22.2B. Regarding current trading prices, GENE is priced at $0.77, while DGX trades at $200.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DGX's P/E ratio is 22.15. In terms of profitability, GENE's ROE is -1.85%, compared to DGX's ROE of +0.14%. Regarding short-term risk, GENE is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check DGX's competition here
GENE vs LH Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, LH has a market cap of 21.7B. Regarding current trading prices, GENE is priced at $0.77, while LH trades at $265.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas LH's P/E ratio is 23.46. In terms of profitability, GENE's ROE is -1.85%, compared to LH's ROE of +0.11%. Regarding short-term risk, GENE is less volatile compared to LH. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check LH's competition here
GENE vs EXAS Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GENE is priced at $0.77, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GENE's ROE is -1.85%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, GENE and EXAS have similar daily volatility (0.00).Check EXAS's competition here
GENE vs GH Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GH has a market cap of 16.7B. Regarding current trading prices, GENE is priced at $0.77, while GH trades at $125.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GH's P/E ratio is -36.94. In terms of profitability, GENE's ROE is -1.85%, compared to GH's ROE of +1.84%. Regarding short-term risk, GENE is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check GH's competition here
GENE vs PKI Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GENE is priced at $0.77, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PKI's P/E ratio is 41.45. In terms of profitability, GENE's ROE is -1.85%, compared to PKI's ROE of +0.03%. Regarding short-term risk, GENE is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check PKI's competition here
GENE vs MEDP Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MEDP has a market cap of 13B. Regarding current trading prices, GENE is priced at $0.77, while MEDP trades at $454.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MEDP's P/E ratio is 28.62. In terms of profitability, GENE's ROE is -1.85%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, GENE is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MEDP's competition here
GENE vs ICLR Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ICLR has a market cap of 11.4B. Regarding current trading prices, GENE is priced at $0.77, while ICLR trades at $149.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ICLR's P/E ratio is 51.53. In terms of profitability, GENE's ROE is -1.85%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, GENE is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check ICLR's competition here
GENE vs RVTY Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, RVTY has a market cap of 11B. Regarding current trading prices, GENE is priced at $0.77, while RVTY trades at $98.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas RVTY's P/E ratio is 47.28. In terms of profitability, GENE's ROE is -1.85%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, GENE is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check RVTY's competition here
GENE vs CRL Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CRL has a market cap of 8.7B. Regarding current trading prices, GENE is priced at $0.77, while CRL trades at $181.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CRL's P/E ratio is -48.87. In terms of profitability, GENE's ROE is -1.85%, compared to CRL's ROE of -0.06%. Regarding short-term risk, GENE is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check CRL's competition here
GENE vs QGEN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, QGEN has a market cap of 7.6B. Regarding current trading prices, GENE is priced at $0.77, while QGEN trades at $36.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas QGEN's P/E ratio is 18.71. In terms of profitability, GENE's ROE is -1.85%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, GENE is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check QGEN's competition here
GENE vs BLLN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BLLN has a market cap of 4.5B. Regarding current trading prices, GENE is priced at $0.77, while BLLN trades at $97.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BLLN's P/E ratio is 179.98. In terms of profitability, GENE's ROE is -1.85%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BLLN's competition here
GENE vs SYNH Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GENE is priced at $0.77, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GENE's ROE is -1.85%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to SYNH. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check SYNH's competition here
GENE vs SHC Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SHC has a market cap of 4.5B. Regarding current trading prices, GENE is priced at $0.77, while SHC trades at $15.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SHC's P/E ratio is 38.10. In terms of profitability, GENE's ROE is -1.85%, compared to SHC's ROE of +0.21%. Regarding short-term risk, GENE is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check SHC's competition here
GENE vs TWST Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, TWST has a market cap of 4.3B. Regarding current trading prices, GENE is priced at $0.77, while TWST trades at $69.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas TWST's P/E ratio is -52.44. In terms of profitability, GENE's ROE is -1.85%, compared to TWST's ROE of -0.17%. Regarding short-term risk, GENE is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check TWST's competition here
GENE vs RDNT Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, GENE is priced at $0.77, while RDNT trades at $54.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas RDNT's P/E ratio is -319.65. In terms of profitability, GENE's ROE is -1.85%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, GENE is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check RDNT's competition here
GENE vs OLK Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GENE is priced at $0.77, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas OLK's P/E ratio is -96.59. In terms of profitability, GENE's ROE is -1.85%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GENE is less volatile compared to OLK. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check OLK's competition here
GENE vs GRAL Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GRAL has a market cap of 2.6B. Regarding current trading prices, GENE is priced at $0.77, while GRAL trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GRAL's P/E ratio is -5.82. In terms of profitability, GENE's ROE is -1.85%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, GENE is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check GRAL's competition here
GENE vs NEOG Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NEOG has a market cap of 1.9B. Regarding current trading prices, GENE is priced at $0.77, while NEOG trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NEOG's P/E ratio is -3.18. In terms of profitability, GENE's ROE is -1.85%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, GENE is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NEOG's competition here
GENE vs CDNA Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, GENE is priced at $0.77, while CDNA trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CDNA's P/E ratio is -139.06. In terms of profitability, GENE's ROE is -1.85%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, GENE is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check CDNA's competition here
GENE vs PSNL Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PSNL has a market cap of 954.6M. Regarding current trading prices, GENE is priced at $0.77, while PSNL trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PSNL's P/E ratio is -10.54. In terms of profitability, GENE's ROE is -1.85%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, GENE is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check PSNL's competition here
GENE vs CSTL Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CSTL has a market cap of 637.2M. Regarding current trading prices, GENE is priced at $0.77, while CSTL trades at $21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CSTL's P/E ratio is -50.02. In terms of profitability, GENE's ROE is -1.85%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, GENE is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check CSTL's competition here
GENE vs GRALV Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GENE is priced at $0.77, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GRALV's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to GRALV's ROE of N/A. Regarding short-term risk, GENE is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check GRALV's competition here
GENE vs FLGT Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, FLGT has a market cap of 543.9M. Regarding current trading prices, GENE is priced at $0.77, while FLGT trades at $19.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas FLGT's P/E ratio is -7.98. In terms of profitability, GENE's ROE is -1.85%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, GENE is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check FLGT's competition here
GENE vs MYGN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MYGN has a market cap of 431.6M. Regarding current trading prices, GENE is priced at $0.77, while MYGN trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MYGN's P/E ratio is -1.06. In terms of profitability, GENE's ROE is -1.85%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, GENE is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MYGN's competition here
GENE vs CO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GENE is priced at $0.77, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CO's P/E ratio is 5.06. In terms of profitability, GENE's ROE is -1.85%, compared to CO's ROE of +0.11%. Regarding short-term risk, GENE is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check CO's competition here
GENE vs PRE Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PRE has a market cap of 337.6M. Regarding current trading prices, GENE is priced at $0.77, while PRE trades at $19.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PRE's P/E ratio is -8.07. In terms of profitability, GENE's ROE is -1.85%, compared to PRE's ROE of -0.36%. Regarding short-term risk, GENE is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check PRE's competition here
GENE vs FLDM Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GENE is priced at $0.77, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GENE's ROE is -1.85%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, GENE is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check FLDM's competition here
GENE vs NEO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NEO has a market cap of 283.9M. Regarding current trading prices, GENE is priced at $0.77, while NEO trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NEO's P/E ratio is -14.16. In terms of profitability, GENE's ROE is -1.85%, compared to NEO's ROE of -0.12%. Regarding short-term risk, GENE is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NEO's competition here
GENE vs OPGN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, GENE is priced at $0.77, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas OPGN's P/E ratio is 132.83. In terms of profitability, GENE's ROE is -1.85%, compared to OPGN's ROE of +1.58%. Regarding short-term risk, GENE and OPGN have similar daily volatility (0.00).Check OPGN's competition here
GENE vs IMDX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, IMDX has a market cap of 140.6M. Regarding current trading prices, GENE is priced at $0.77, while IMDX trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas IMDX's P/E ratio is -3.47. In terms of profitability, GENE's ROE is -1.85%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, GENE is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check IMDX's competition here
GENE vs GTH Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GENE is priced at $0.77, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GTH's P/E ratio is -1.11. In terms of profitability, GENE's ROE is -1.85%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GENE is less volatile compared to GTH. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check GTH's competition here
GENE vs BDSX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BDSX has a market cap of 125.8M. Regarding current trading prices, GENE is priced at $0.77, while BDSX trades at $15.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BDSX's P/E ratio is -3.90. In terms of profitability, GENE's ROE is -1.85%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, GENE is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BDSX's competition here
GENE vs XGN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, XGN has a market cap of 103.6M. Regarding current trading prices, GENE is priced at $0.77, while XGN trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas XGN's P/E ratio is -4.77. In terms of profitability, GENE's ROE is -1.85%, compared to XGN's ROE of -1.14%. Regarding short-term risk, GENE is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check XGN's competition here
GENE vs STIM Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, STIM has a market cap of 89.8M. Regarding current trading prices, GENE is priced at $0.77, while STIM trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas STIM's P/E ratio is -2.39. In terms of profitability, GENE's ROE is -1.85%, compared to STIM's ROE of -1.65%. Regarding short-term risk, GENE is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check STIM's competition here
GENE vs SERA Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SERA has a market cap of 85.2M. Regarding current trading prices, GENE is priced at $0.77, while SERA trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SERA's P/E ratio is -3.48. In terms of profitability, GENE's ROE is -1.85%, compared to SERA's ROE of -0.41%. Regarding short-term risk, GENE is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check SERA's competition here
GENE vs ATLN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ATLN has a market cap of 79.2M. Regarding current trading prices, GENE is priced at $0.77, while ATLN trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ATLN's P/E ratio is -0.92. In terms of profitability, GENE's ROE is -1.85%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, GENE is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check ATLN's competition here
GENE vs DRIO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DRIO has a market cap of 54.8M. Regarding current trading prices, GENE is priced at $0.77, while DRIO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DRIO's P/E ratio is -0.88. In terms of profitability, GENE's ROE is -1.85%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, GENE is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check DRIO's competition here
GENE vs PRPO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PRPO has a market cap of 42M. Regarding current trading prices, GENE is priced at $0.77, while PRPO trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PRPO's P/E ratio is -52.20. In terms of profitability, GENE's ROE is -1.85%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, GENE is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check PRPO's competition here
GENE vs STRR Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, STRR has a market cap of 41.8M. Regarding current trading prices, GENE is priced at $0.77, while STRR trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas STRR's P/E ratio is -4.53. In terms of profitability, GENE's ROE is -1.85%, compared to STRR's ROE of -0.14%. Regarding short-term risk, GENE is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check STRR's competition here
GENE vs STRRP Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, STRRP has a market cap of 33M. Regarding current trading prices, GENE is priced at $0.77, while STRRP trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas STRRP's P/E ratio is -4.87. In terms of profitability, GENE's ROE is -1.85%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, GENE is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check STRRP's competition here
GENE vs MDXH Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MDXH has a market cap of 29.1M. Regarding current trading prices, GENE is priced at $0.77, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MDXH's P/E ratio is -0.87. In terms of profitability, GENE's ROE is -1.85%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, GENE is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MDXH's competition here
GENE vs QUCY Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, QUCY has a market cap of 27.5M. Regarding current trading prices, GENE is priced at $0.77, while QUCY trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas QUCY's P/E ratio is -0.10. In terms of profitability, GENE's ROE is -1.85%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, GENE is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check QUCY's competition here
GENE vs AKU Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GENE is priced at $0.77, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas AKU's P/E ratio is -0.13. In terms of profitability, GENE's ROE is -1.85%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GENE is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check AKU's competition here
GENE vs CEMI Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GENE is priced at $0.77, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GENE's ROE is -1.85%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GENE and CEMI have similar daily volatility (0.00).Check CEMI's competition here
GENE vs ENZ Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GENE is priced at $0.77, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ENZ's P/E ratio is -2.85. In terms of profitability, GENE's ROE is -1.85%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, GENE is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check ENZ's competition here
GENE vs PMD Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GENE is priced at $0.77, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PMD's P/E ratio is -5.24. In terms of profitability, GENE's ROE is -1.85%, compared to PMD's ROE of -0.32%. Regarding short-term risk, GENE and PMD have similar daily volatility (0.00).Check PMD's competition here
GENE vs ME Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GENE is priced at $0.77, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ME's P/E ratio is -0.03. In terms of profitability, GENE's ROE is -1.85%, compared to ME's ROE of -7.71%. Regarding short-term risk, GENE and ME have similar daily volatility (0.00).Check ME's competition here
GENE vs MYNZ Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GENE is priced at $0.77, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, GENE's ROE is -1.85%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, GENE is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MYNZ's competition here
GENE vs CHEK Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GENE is priced at $0.77, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GENE's ROE is -1.85%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GENE is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check CHEK's competition here
GENE vs BNR Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BNR has a market cap of 10M. Regarding current trading prices, GENE is priced at $0.77, while BNR trades at $9.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BNR's P/E ratio is -12.19. In terms of profitability, GENE's ROE is -1.85%, compared to BNR's ROE of -0.10%. Regarding short-term risk, GENE is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BNR's competition here
GENE vs VNRX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, VNRX has a market cap of 9.6M. Regarding current trading prices, GENE is priced at $0.77, while VNRX trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas VNRX's P/E ratio is -0.42. In terms of profitability, GENE's ROE is -1.85%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, GENE is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check VNRX's competition here
GENE vs CNTG Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GENE is priced at $0.77, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GENE's ROE is -1.85%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GENE and CNTG have similar daily volatility (0.00).Check CNTG's competition here
GENE vs MBAI Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MBAI has a market cap of 8.1M. Regarding current trading prices, GENE is priced at $0.77, while MBAI trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MBAI's P/E ratio is 2.09. In terms of profitability, GENE's ROE is -1.85%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, GENE is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MBAI's competition here
GENE vs BIAF Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BIAF has a market cap of 7.8M. Regarding current trading prices, GENE is priced at $0.77, while BIAF trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BIAF's P/E ratio is -0.37. In terms of profitability, GENE's ROE is -1.85%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, GENE is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BIAF's competition here
GENE vs APDN Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GENE is priced at $0.77, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas APDN's P/E ratio is -0.10. In terms of profitability, GENE's ROE is -1.85%, compared to APDN's ROE of -6.53%. Regarding short-term risk, GENE is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check APDN's competition here
GENE vs TRIB Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, TRIB has a market cap of 6.9M. Regarding current trading prices, GENE is priced at $0.77, while TRIB trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas TRIB's P/E ratio is -0.33. In terms of profitability, GENE's ROE is -1.85%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, GENE is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check TRIB's competition here
GENE vs NOTV Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NOTV has a market cap of 5.7M. Regarding current trading prices, GENE is priced at $0.77, while NOTV trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NOTV's P/E ratio is -0.07. In terms of profitability, GENE's ROE is -1.85%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GENE is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NOTV's competition here
GENE vs NVTA Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GENE is priced at $0.77, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GENE's ROE is -1.85%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GENE is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NVTA's competition here
GENE vs LMDX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GENE is priced at $0.77, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GENE is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check LMDX's competition here
GENE vs LMDXW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GENE is priced at $0.77, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GENE's ROE is -1.85%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GENE is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check LMDXW's competition here
GENE vs ADVB Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ADVB has a market cap of 4.5M. Regarding current trading prices, GENE is priced at $0.77, while ADVB trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ADVB's P/E ratio is 1.04. In terms of profitability, GENE's ROE is -1.85%, compared to ADVB's ROE of -0.65%. Regarding short-term risk, GENE is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check ADVB's competition here
GENE vs BGLC Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BGLC has a market cap of 4.4M. Regarding current trading prices, GENE is priced at $0.77, while BGLC trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BGLC's P/E ratio is -1.46. In terms of profitability, GENE's ROE is -1.85%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, GENE is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BGLC's competition here
GENE vs BNGO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BNGO has a market cap of 3.8M. Regarding current trading prices, GENE is priced at $0.77, while BNGO trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BNGO's P/E ratio is -0.26. In terms of profitability, GENE's ROE is -1.85%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, GENE is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BNGO's competition here
GENE vs DMTK Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GENE is priced at $0.77, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GENE's ROE is -1.85%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GENE is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check DMTK's competition here
GENE vs NDRA Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NDRA has a market cap of 3.2M. Regarding current trading prices, GENE is priced at $0.77, while NDRA trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NDRA's P/E ratio is -0.52. In terms of profitability, GENE's ROE is -1.85%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, GENE is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NDRA's competition here
GENE vs SQL Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GENE is priced at $0.77, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SQL's P/E ratio is -0.40. In terms of profitability, GENE's ROE is -1.85%, compared to SQL's ROE of +2.74%. Regarding short-term risk, GENE is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check SQL's competition here
GENE vs AWH Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GENE is priced at $0.77, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas AWH's P/E ratio is -0.09. In terms of profitability, GENE's ROE is -1.85%, compared to AWH's ROE of +2.03%. Regarding short-term risk, GENE and AWH have similar daily volatility (0.00).Check AWH's competition here
GENE vs INBS Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, GENE is priced at $0.77, while INBS trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas INBS's P/E ratio is -0.21. In terms of profitability, GENE's ROE is -1.85%, compared to INBS's ROE of -1.74%. Regarding short-term risk, GENE is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check INBS's competition here
GENE vs HTGM Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GENE is priced at $0.77, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GENE's ROE is -1.85%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GENE and HTGM have similar daily volatility (0.00).Check HTGM's competition here
GENE vs BIAFW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BIAFW has a market cap of 905.5K. Regarding current trading prices, GENE is priced at $0.77, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BIAFW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, GENE is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BIAFW's competition here
GENE vs BIOC Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GENE is priced at $0.77, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GENE is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BIOC's competition here
GENE vs ISPC Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ISPC has a market cap of 419.4K. Regarding current trading prices, GENE is priced at $0.77, while ISPC trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ISPC's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, GENE is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check ISPC's competition here
GENE vs PRENW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PRENW has a market cap of 224.8K. Regarding current trading prices, GENE is priced at $0.77, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PRENW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, GENE is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check PRENW's competition here
GENE vs SQLLW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, GENE is priced at $0.77, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, GENE is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check SQLLW's competition here
GENE vs TTOO Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, TTOO has a market cap of 11.2K. Regarding current trading prices, GENE is priced at $0.77, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas TTOO's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, GENE is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check TTOO's competition here
GENE vs NDRAW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, GENE is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check NDRAW's competition here
GENE vs OCDX Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GENE's ROE is -1.85%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GENE is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check OCDX's competition here
GENE vs BNGOW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, GENE is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check BNGOW's competition here
GENE vs PRXL Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PRXL's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GENE is less volatile compared to PRXL. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check PRXL's competition here
GENE vs CHEKZ Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GENE is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check CHEKZ's competition here
GENE vs MEUSW Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, GENE is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check MEUSW's competition here
GENE vs DHR-PA Comparison June 2026
GENE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GENE's ROE is -1.85%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, GENE is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for GENE.Check DHR-PA's competition here